

Revision date: 12-Apr-2015 Version: 1.2 Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Ketobemidone Hydrochloride Tablets

Trade Name: Ketogan; Ketogan Novum; KETORAX

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as opioid analgesic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017

1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd

Ramsgate Road Sandwich, Kent CT13 9NJ

United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Australian Hazard Classification

(NOHSC):

No data available

Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Material Name: Ketobemidone Hydrochloride Tablets

Revision date: 12-Apr-2015 Version: 1.2

| 3. COMPOSITION / INFORMATION ON INGREDIENTS | | | | | | | | |
|---|------------|---------------------|-------------------|-----------------------|-----|--|--|--|
| Ingredient | CAS Number | EU EINECS/ELINCS | EU Classification | GHS Classification | % | | | |
| | | List | | | | | | |
| Talc (non-asbestiform) | 14807-96-6 | 238-877-9 | Not Listed | Not Listed | * | | | |
| Magnesium stearate | 557-04-0 | 209-150-3 | Not Listed | Not Listed | * | | | |
| Starch | 9005-25-8 | 232-679-6 | Not Listed | Not Listed | * | | | |
| Ketobemidone Hydrochloride | 5965-49-1 | 227-749-8 | Xn:R22 | Acute Tox.4 (H302) | 3.6 | | | |

| Ingredient | CAS Number | EU EINECS/ELINCS List | EU Classification | GHS Classification | % |
|---------------------|------------|-----------------------------|-------------------|-----------------------|---|
| Lactose Monohydrate | 64044-51-5 | Not Listed | Not Listed | Not Listed | * |
| Povidone | 9003-39-8 | Not Listed | Not Listed | Not Listed | * |
| Gelatin | 9000-70-8 | 232-554-6 | Not Listed | Not Listed | * |

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

Page 2 of 9

mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical

attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride,

Products: and other chlorine-containing compounds.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

Material Name: Ketobemidone Hydrochloride Tablets

Revision date: 12-Apr-2015 Version: 1.2

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source or

Collecting:

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

Page 3 of 9

dry solids. Clean spill area thoroughly.

Additional Consideration for

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Talc (non-asbestiform)

ACGIH Threshold Limit Value (TWA) 2 mg/m³ 2.5 mg/m³ **Australia TWA** 2 mg/m³ **Austria OEL - MAKs Belgium OEL - TWA** 2 mg/m^3 1.0 fiber/cm3 **Bulgaria OEL - TWA** 6.0 mg/m³ 3.0 mg/m³ 2.0 mg/m³ Czech Republic OEL - TWA **Denmark OEL - TWA** 0.3 fiber/cm3 **Finland OEL - TWA** 0.5 fiber/cm3 10 ma/m³ **Greece OEL - TWA**

| 2 mg/m³ | Hungary OEL - TWA | 2 mg/m³ | Ireland OEL - TWAs | 10 mg/m³ | 0.8 mg/m³ | Lithuania OEL - TWA | 2 mg/m³ |

1 mg/m³

Netherlands OEL - TWA 0.25 mg/m³

Material Name: Ketobemidone Hydrochloride Tablets

Revision date: 12-Apr-2015

Page 4 of 9

Version: 1.2

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

| OSHA - Final PELs - Table Z-3 Mineral D: | 20 mppcf |
|--|-----------------------|
| Poland OEL - TWA | 4.0 mg/m ³ |
| | 1.0 mg/m ³ |
| Portugal OEL - TWA | 2 mg/m³ |
| Romania OEL - TWA | 2 mg/m³ |
| Slovakia OEL - TWA | 2 mg/m³ |
| | 10 mg/m ³ |
| Slovenia OEL - TWA | 2 mg/m³ |
| Spain OEL - TWA | 2 mg/m ³ |
| Sweden OEL - TWAs | 2 mg/m³ |
| | 1 mg/m³ |
| Switzerland OEL -TWAs | 2 mg/m ³ |
| | |

Magnesium stearate

ACGIH Threshold Limit Value (TWA)

Lithuania OEL - TWA

Sweden OEL - TWAs

5 mg/m³

5 mg/m³

Starch

| • | |
|-----------------------------------|------------------------|
| ACGIH Threshold Limit Value (TWA) | 10 mg/m ³ |
| Australia TWA | 10 mg/m ³ |
| Belgium OEL - TWA | 10 mg/m ³ |
| Bulgaria OEL - TWA | 10.0 mg/m ³ |
| Czech Republic OEL - TWA | 4.0 mg/m ³ |
| Greece OEL - TWA | 10 mg/m ³ |
| | 5 mg/m ³ |
| Ireland OEL - TWAs | 10 mg/m ³ |
| | 4 mg/m³ |
| OSHA - Final PELS - TWAs: | 15 mg/m ³ |
| Portugal OEL - TWA | 10 mg/m ³ |
| Slovakia OEL - TWA | 4 mg/m ³ |
| Spain OEL - TWA | 10 mg/m ³ |
| Switzerland OEL -TWAs | 3 mg/m ³ |

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Ketobemidone Hydrochloride

Pfizer Occupational Exposure OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Band (OEB):

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep air contamination levels below the exposure limits or within the OEB range listed above in this

section.

Personal Protective

Equipment:

Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Material Name: Ketobemidone Hydrochloride Tablets Page 5 of 9

Revision date: 12-Apr-2015 Version: 1.2

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection,

with appropriate protection factors, should be used to minimize exposure.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablets Color: White

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility:
Water Solubility:
PH:
No data available
No data available
No data available.
No data available.
No data available.
No data available
No data available
Partition Coefficient: (Method, pH, Endpoint, Value)

Ketobemidone No data available

Ketobemidone Hydrochloride

No data available **Lactose Monohydrate**No data available

Povidone

No data available

Starch

No data available

Gelatin

No data available

Talc (non-asbestiform)

No data available

Magnesium stearate

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):No data availableFlammability (Solids):No data availableFlash Point (Liquid) (°C):No data availableUpper Explosive Limits (Liquid) (% by Vol.):No data availableLower Explosive Limits (Liquid) (% by Vol.):No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Material Name: Ketobemidone Hydrochloride Tablets

Version: 1.2 Revision date: 12-Apr-2015

10. STABILITY AND REACTIVITY

Oxidizing Properties: No data available **Conditions to Avoid:** None known

As a precautionary measure, keep away from strong oxidizers **Incompatible Materials:**

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of various forms of the

active ingredient. The remaining information describes the potential hazards of the individual

Page 6 of 9

inaredients.

Short Term: Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: May cause effects similar to those seen in clinical use including dry mouth, blurred vision,

> constipation, and upset stomach. Ingestion of this material may cause effects similar to those seen in clinical use including hypotension (low blood pressure), dizziness, headache and

drowsiness.

Acute Toxicity: (Species, Route, End Point, Dose)

Ketobemidone

Rat Intravenous LD 50 10 mg/kg

Mouse LD 50 14mg/kg

Ketobemidone Hydrochloride

215 mg/kg Oral LD 50

Rat Para-periosteal LD 50 40mg/kg

Lactose Monohydrate

Rat Oral LD 50 29700 mg/kg

Povidone

Rat Oral LD50 100 g/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Magnesium stearate

Oral LD50 > 2000 mg/kg Inhalation LC50 $> 2000 \text{ mg/m}^3$

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Lactose Monohydrate

In Vitro Bacterial Mutagenicity (Ames) Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Povidone

Group 3 (Not Classifiable) IARC:

Material Name: Ketobemidone Hydrochloride Tablets

Revision date: 12-Apr-2015 Version: 1.2

11. TOXICOLOGICAL INFORMATION

Talc (non-asbestiform)

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

Page 7 of 9

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

232-679-6

Page 8 of 9

Material Name: Ketobemidone Hydrochloride Tablets

Revision date: 12-Apr-2015 Version: 1.2

15. REGULATORY INFORMATION

Lactose Monohydrate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Australia (AICS):

REACH - Annex IV - Exemptions from the

Not Listed

Not Listed

Not Listed

Present

obligations of Register:

EU EINECS/ELINCS List Not Listed

Talc (non-asbestiform)

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Present

238-877-9

Magnesium stearate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Present

Present

209-150-3

Starch

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the obligations of Register:

Not Listed

Not Listed

Not Listed

Not Listed

Present

Present

Povidone

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Gelatin

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Present

232-554-6

Ketobemidone Hydrochloride

EU EINECS/ELINCS List

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed
227-749-8

Additional Information: U.S. Drug Enforcement Agency Controlled Drug Substance, Schedule I

Material Name: Ketobemidone Hydrochloride Tablets Page 9 of 9 Version: 1.2

Revision date: 12-Apr-2015

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Xn - Harmful

R22 - Harmful if swallowed.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated

Section 8 - Exposure Controls / Personal Protection.

Revision date: 12-Apr-2015

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet